Liz Cramer is an oncology molecular diagnostics sales leader passionate about improving oncology healthcare delivery through the integration of genetic and genomic technologies.

 

Liz excels at bringing internal and external stakeholders together to work towards shared goals and inspiring her team to achieve their greatest potential. Every day Liz's goal is to connect people, improve care, and deliver better patient outcomes.

​

Liz's strengths stem from a versatile skill set, allowing her to take on diverse projects and cross-functional leadership positions.

 

A deeply analytical mind able to identify patterns in data to inform sound decision making, a natural idea generator - not afraid of asking "what if we?", a technically adept and charismatic client presence, and an engrained desire to win have resulted in a 20 year award-winning sales growth track record individually, and for the teams she has been honored to serve.

​

An experienced go-to-market sales leader, Liz has launched 13+ oncology molecular diagnostics, oncology companion diagnostics, cancer genetic tests, medical devices, and pharmaceuticals over the last 20 years.

 

Currently, Liz leads a diagnostic oncology sales team of District Managers, Clinical Oncology Specialists, and junior sales associates as a Regional Director at Natera Oncology. Natera's novel assay, Signatera, is the first patient-specific circulating tumor DNA (ctDNA) monitoring assay available for clinical use. Signatera detects the presence or absence of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment for patients previously diagnosed with cancer. 

Previously as Regional Business Director, at Caris Life Sciences​ Liz led a team covering oncology practices and major NCI designated cancer centers within four states. Caris offers a comprehensive genomic profiling service for advanced cancer patients inclusive of Next-Generation DNA Sequencing, RNA Whole Transcriptome Sequencing, Proteomics, immunotherapy diagnostics and clinical trial matching.

While at Myriad Genetic Laboratories, Liz challenged a 15 year old notion, spearheading an initiative that opened access to cancer genetic testing for over 8,000 underserved patients in Maryland.

Outside of industry, Liz served as an Executive member of the Founding Board of Directors of Breast Care for Washington (BCW). Ms. Cramer lead BCW's launch marketing strategy, developing BCW's online presence, to take the organization from a grassroots initiative to serving patients within two years. BCW's mission is to provide breast cancer screening and diagnostics to all women, regardless of ability to pay.

 

As part of the Rare Genomics Institute Scientific team, Liz served as Scientific Marketing Lead, Genomics, working with a team of PhD's to develop pre-launch strategy for rareREACH, an online database used to match patients with rare diseases with researchers, in hopes of a diagnosis and treatment.
​
Liz has a special interest in developing future female leaders and currently serves as Chair of Women of Natera. WoN is a powerful employee resource group that has been instrumental in leading change at an organizational level. 24% of Natera employees are members of WoN.

Liz holds an M.B.A. from the University of Maryland, and a B.A. in Economics from Bucknell University.​